Skip to Main ContentSkip to FooterSkip to Search
Main menu
  1. Home
  2.  » 
  3. Events
  4.  » Inhalation & Respiratory Drug Delivery USA Congress
Inhalation & Respiratory Drug Delivery USA Congress



Carolyn Berg's headshot

Carolyn Berg
Vice President, Business Development – Inhalation, Catalent




Session Title: Novel Opportunities for Dry Powder Formulations for Pulmonary and Nasal Delivery
Session Date: Tuesday, October 11, 2022
Session Time: 10:15AM – 10:45AM PT
Abstract: Pulmonary and nasal delivery have been the preferred routes of administration for locally acting drugs exerting their effects in the airways or nasal mucosa. In recent decades, drugs delivered via the pulmonary route were primarily for indications such as asthma and COPD, while drugs delivered by the nasal route were for allergic rhinitis. For both routes of administration, molecules were mainly highly potent, small molecules where pulmonary products were primarily delivered via metered dose inhalers or nebulized solutions while nasal products were delivered as liquid solutions or suspensions.  The scientific pipeline has expanded to include high dose small molecules or inhaled biotherapeutic (peptides, proteins, gene therapies, phages) as alternatives to injection and sub-cutaneous dosage forms. For this reason, new technologies for the development of dry powders for inhalation such as spray drying have been gaining traction to address the complexity of delivering these newer molecules through the pulmonary or nasal route. Factors such as molecule potency, powder collection mechanisms, environmental controls and filling and assembling capabilities for the variety of devices used to deliver these drugs are important considerations for pharmaceutical companies when developing these drugs. The challenges and development aspects of dry powder inhalation will be addressed.